FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...

A U.S. research team has developed the first-ever artificial intelligence (AI) model capable of predicting over 100 health ...

The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) has recognized Midland Memorial ...

Treatment with semaglutide has been shown to reduce the total number of hospital admissions and the duration of stays in patients with established cardiovascular disease (CVD) and overweight or ...

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk reduction.

Celebrating Scientific Advancement Amarin applauds the groundbreaking work addressing sHTG and rare genetic disorders such as familial chylomicronemia syndrome (FCS). These advances help drive patient ...

Professor Thomas F. Lüscher discusses the new ESC clinical consensus statement on vaccination and its pivotal role in ...

Following the January 2025 wildfires affecting Los Angeles, there was an increase in emergency encounters for certain diagnoses.

Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, ...

For women with severe CAD, percutaneous coronary intervention is associated with increased risk for MACCE and all-cause mortality compared with CABG.